Home » Stocks » OFIX

Orthofix Medical Inc. (OFIX)

Stock Price: $43.93 USD 0.35 (0.80%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 849.33M
Revenue (ttm) 410.44M
Net Income (ttm) 23.58M
Shares Out 19.34M
EPS (ttm) 1.21
PE Ratio 36.19
Forward PE 59.88
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $43.93
Previous Close $43.58
Change ($) 0.35
Change (%) 0.80%
Day's Open 43.07
Day's Range 42.69 - 43.97
Day's Volume 78,254
52-Week Range 22.73 - 46.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2020 net sales of approximately $118 million, a decrease of 3% on a...

Business Wire - 2 weeks ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will part...

Business Wire - 2 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek will participate in a fireside chat during the ...

Seeking Alpha - 2 months ago

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Orthofix (OFIX) delivered earnings and revenue surprises of 247.62% and 29.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2020. Net sales were $111.0 million, earn...

Zacks Investment Research - 2 months ago

Orthofix (OFIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to rel...

Zacks Investment Research - 3 months ago

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced support for the U.S.

Forbes - 5 months ago

Investors continue to hope for a generous fiscal package to tackle the pandemic, but remain cautious of the developments so far as the process has become highly politicized. Our deep learning ...

Other stocks mentioned: CACI, PLUS, SYX, TGNA
Seeking Alpha - 5 months ago

Orthofix Medical, Inc. (OFIX) CEO Jon Serbousek on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Orthofix (OFIX) delivered earnings and revenue surprises of 26.25% and 35.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2020.

Business Wire - 5 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek will present at the Canaccord Genuity 40th Annu...

Zacks Investment Research - 5 months ago

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to rel...

Zacks Investment Research - 6 months ago

Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.

Seeking Alpha - 8 months ago

Orthofix Medical, Inc. (OFIX) CEO Jon Serbousek on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Orthofix (OFIX) delivered earnings and revenue surprises of -18.18% and 0.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.

Other stocks mentioned: ABMD, BDX
Zacks Investment Research - 10 months ago

Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.

Zacks Investment Research - 10 months ago

We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.

Seeking Alpha - 10 months ago

Orthofix Medical, Inc. (OFIX) CEO Jon Serbousek on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Orthofix (OFIX) delivered earnings and revenue surprises of 0.00% and -1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Orthofix Medical, Inc. (OFIX) CEO Bradley Mason on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Orthofix (OFIX) delivered earnings and revenue surprises of -21.15% and -4.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

Other stocks mentioned: MDT, SYK
Zacks Investment Research - 1 year ago

Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

Seeking Alpha - 1 year ago

Orthofix Medical, Inc. (OFIX) CEO Bradley Mason on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Orthofix (OFIX) delivered earnings and revenue surprises of -30.00% and 0.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

Other stocks mentioned: BIOL, DXCM, HAE
Seeking Alpha - 1 year ago

Orthofix Medical, Inc. (OFIX) CEO Brad Mason on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Orthofix (OFIX) delivered earnings and revenue surprises of -32.50% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

The primary goal of the study was to assess the safety and efficacy of Orthofix's M6-C artificial cervical disc in comparison to ACDF treatment.

About OFIX

Orthofix Medical, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion as well as used as a therapeutic treatment for non-spinal appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical pr... [Read more...]

Industry
Medical Devices
Founded
1987
CEO
Jon C. Serbousek
Employees
1,055
Stock Exchange
NASDAQ
Ticker Symbol
OFIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for OFIX stock is "Buy." The 12-month stock price forecast is 49.31, which is an increase of 12.25% from the latest price.

Price Target
$49.31
(12.25% upside)
Analyst Consensus: Buy